A Phase 1 interventional study of MT-8554 low dose and MT-8554 high dose in Healthy, sponsored by Tanabe Pharma Corporation. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-22.
Sponsored by Tanabe Pharma Corporation · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to investigate the pharmacodynamic effect of single doses of MT-8554 in healthy subjects.
Tanabe Pharma Corporation is the lead sponsor of 92 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: MT-8554 low dose, Period 2: MT-8554 high dose, Period 3: Placebo and Period 4: Oxycodone hydrochloride, respectively single dosing
Drug: MT-8554 low dose · Drug: MT-8554 high dose · Drug: Oxycodone hydrochloride · Drug: Placebo
Period 1: MT-8554 high dose, Period 2: Oxycodone hydrochloride, Period 3: MT-8554 low dose and Period 4: Placebo, respectively single dosing
Drug: MT-8554 low dose · Drug: MT-8554 high dose · Drug: Oxycodone hydrochloride · Drug: Placebo
Period 1: Placebo, Period 2: MT-8554 low dose, Period 3: Oxycodone hydrochloride and Period 4: MT-8554 high dose, respectively single dosing
Drug: MT-8554 low dose · Drug: MT-8554 high dose · Drug: Oxycodone hydrochloride · Drug: Placebo
Period 1: Oxycodone hydrochloride, Period 2: Placebo, Period 3: MT-8554 high dose and Period 4: MT-8554 low dose, respectively single dosing
Drug: MT-8554 low dose · Drug: MT-8554 high dose · Drug: Oxycodone hydrochloride · Drug: Placebo
Pharmacodynamic effect as measured by Visual Analogue Scale for Cold Pressor Test
Time frame: up to 10 hours post dosing
Safety and Tolerability as measured by vital signs
Time frame: up to Day6 of treatment period 4
Safety and Tolerability as measured by ECG
Time frame: up to Day6 of treatment period 4
Safety and Tolerability as measured by laboratory safety assessments
Time frame: up to Day6 of treatment period 4
Safety and Tolerability as measured by physical examination
Time frame: up to Day6 of treatment period 4
Safety and Tolerability as measured by number of participants with adverse events
Time frame: up to Day6 of treatment period 4
Plasma concentration of MT-8554 at the time of Pharmacodynamic assessments
Time frame: up to 10 hours post dosing
Plasma concentration of Oxycodone hydrochloride at the time of Pharmacodynamic assessments
Time frame: up to 10 hours post dosing
The record gives a start of Aug 2015, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elismetrep